(NASDAQ: AVLN) Avalyn Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.5%.
Avalyn Pharma's earnings in 2026 is N/A.On average, 3 Wall Street analysts forecast AVLN's earnings for 2026 to be -$113,953,787, with the lowest AVLN earnings forecast at -$109,485,011, and the highest AVLN earnings forecast at -$117,305,369. On average, 5 Wall Street analysts forecast AVLN's earnings for 2027 to be -$102,347,383, with the lowest AVLN earnings forecast at -$109,919,476, and the highest AVLN earnings forecast at -$82,858,555.
In 2028, AVLN is forecast to generate -$103,101,046 in earnings, with the lowest earnings forecast at -$119,043,227 and the highest earnings forecast at -$84,720,545.